Hepion Capital Surpluse vs Other Current Liab Analysis
HEPA Stock | USD 1.17 0.13 10.00% |
Hepion Pharmaceuticals financial indicator trend analysis is much more than just examining Hepion Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Hepion Pharmaceuticals is a good investment. Please check the relationship between Hepion Pharmaceuticals Capital Surpluse and its Other Current Liab accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.
Capital Surpluse vs Other Current Liab
Capital Surpluse vs Other Current Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Hepion Pharmaceuticals Capital Surpluse account and Other Current Liab. At this time, the significance of the direction appears to have weak relationship.
The correlation between Hepion Pharmaceuticals' Capital Surpluse and Other Current Liab is 0.34. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Hepion Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Hepion Pharmaceuticals' Capital Surpluse and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Hepion Pharmaceuticals are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Capital Surpluse i.e., Hepion Pharmaceuticals' Capital Surpluse and Other Current Liab go up and down completely randomly.
Correlation Coefficient | 0.34 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Capital Surpluse
Other Current Liab
Most indicators from Hepion Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Hepion Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.At present, Hepion Pharmaceuticals' Enterprise Value Over EBITDA is projected to drop slightly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.04, whereas Selling General Administrative is forecasted to decline to about 6.5 M.
Hepion Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Hepion Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Hepion Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 20.6M | 48.6M | 103.6M | 60.2M | 18.1M | 27.5M | |
Other Current Liab | 851.2K | 659.6K | 3.0M | 366.2K | 386K | 366.7K | |
Total Current Liabilities | 1.6M | 4.7M | 8.2M | 7.9M | 5.3M | 3.8M | |
Total Stockholder Equity | 15.6M | 40.5M | 93.0M | 49.9M | 7.3M | 6.9M | |
Net Debt | (13.1M) | (40.0M) | (91.0M) | (51.1M) | (14.6M) | (15.3M) | |
Retained Earnings | (83.8M) | (104.1M) | (133.5M) | (175.7M) | (224.6M) | (213.4M) | |
Accounts Payable | 491.6K | 3.7M | 2.4M | 2.7M | 2.3M | 2.0M | |
Cash | 13.9M | 40.7M | 91.3M | 51.2M | 14.8M | 22.3M | |
Cash And Short Term Investments | 13.9M | 40.7M | 91.3M | 51.2M | 14.8M | 24.2M | |
Common Stock Total Equity | 1.7K | 375.0 | 3.2K | 7.6K | 8.8K | 9.2K | |
Common Stock Shares Outstanding | 102.2K | 483.9K | 3.5M | 3.8M | 4.0M | 4.2M | |
Liabilities And Stockholders Equity | 20.6M | 48.6M | 103.6M | 60.2M | 18.1M | 27.5M | |
Non Current Liabilities Total | 3.4M | 3.5M | 2.4M | 2.5M | 5.5M | 4.0M | |
Other Stockholder Equity | 97.7M | 142.9M | 224.8M | 223.9M | 230.3M | 241.8M | |
Total Liab | 5.0M | 8.1M | 10.6M | 10.4M | 10.8M | 7.7M | |
Total Current Assets | 14.4M | 42.6M | 97.5M | 56.5M | 17.5M | 24.0M | |
Common Stock | 25.0 | 375.0 | 3.2K | 7.6K | 482.0 | 457.9 | |
Non Currrent Assets Other | 306.9K | 285.1K | 583.3K | 426.2K | 301.7K | 222.4K | |
Property Plant And Equipment Gross | 855.1K | 108.4K | 696.7K | 439.2K | 621.8K | 652.9K | |
Property Plant And Equipment Net | 855.1K | 664.9K | 456.5K | 132.2K | 242.4K | 289.1K | |
Non Current Assets Total | 6.2M | 6.0M | 6.1M | 3.7M | 606.6K | 576.2K | |
Other Assets | 3.3M | 4.0M | 583.3K | 426.2K | 490.1K | 465.6K | |
Capital Surpluse | 76.7M | 97.7M | 142.9M | 223.9M | 257.5M | 270.4M | |
Other Current Assets | 465.7K | 1.9M | 6.1M | 5.3M | 2.7M | 2.0M | |
Property Plant Equipment | 855.1K | 664.9K | 456.5K | 81.6K | 93.9K | 89.2K | |
Short Long Term Debt Total | 807.4K | 752.2K | 317.0K | 53.6K | 209.0K | 360.0K | |
Other Liab | 2.5M | 3.0M | 2.3M | 2.5M | 2.3M | 3.2M | |
Net Tangible Assets | 12.6M | 36.9M | 86.2M | 45.0M | 51.7M | 54.3M | |
Non Current Liabilities Other | 2.4M | 2.6M | 1.9M | 2.1M | 1.6M | 2.0M | |
Net Invested Capital | 14.5M | 39.0M | 91.3M | 48.2M | 5.6M | 5.3M | |
Net Working Capital | 13.1M | 38.0M | 89.2M | 48.6M | 12.2M | 11.6M | |
Short Term Debt | 266.7K | 279.8K | 266.7K | 53.6K | 115.9K | 110.1K | |
Capital Stock | 1.7M | 1.7M | 1.7M | 1.7M | 1.7M | 1.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Hepion Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hepion Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hepion Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hepion Pharmaceuticals Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Hepion Stock analysis
When running Hepion Pharmaceuticals' price analysis, check to measure Hepion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hepion Pharmaceuticals is operating at the current time. Most of Hepion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hepion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hepion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hepion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Transaction History View history of all your transactions and understand their impact on performance | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is Hepion Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hepion Pharmaceuticals. If investors know Hepion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hepion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.32) | Return On Assets (0.72) | Return On Equity (1.71) |
The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hepion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hepion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.